CoChat
Sign Up
Cited by 314Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

Open access
Soria, J.-C., Mauguen, A., Reck, M., Sandler, A.B., Saijo, N., Johnson, D.H., Burcoveanu, D., Fukuoka, M. +2 more·2013·Annals of Oncology
DOI 10.1093/annonc/mds590
Open this paper in CoChat — free account

Abstract

Background Previous studies have demonstrated the efficacy and safety of bevacizumab in the treatment of non-small-cell lung cancer (NSCLC).Methods Summary data from randomised trials comparing first-line bevacizumab plus platinum-based chemotherapy with chemotherapy alone for inoperable locally advanced, recurrent or metastatic NSCLC were meta-analysed. Pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and pooled odds ratio (OR) for adverse events were calculated. The chi-squared tests evaluated interactions between treatment effects, and prognostic factors and patient characteristics.Results Data of 2194 patients (1313 bevacizumab; 881 controls) from four phase II and III trials: AVF-0757g, JO19907,ECOG 4599 and AVAiL, were analysed. Compared with chemotherapy alone, bevacizumab significantly prolonged OS(HR 0.90; 95% confidence interval [CI] 0.81, 0.99; P=0.03), and PFS (0.72; 95% CI 0.66, 0.79; P<0.001). Bevacizumab showed a significantly greater effect on OS in patients with adenocarcinoma versus other histologies (P=0.03), and patients with body weight loss ≤5% versus >5% (P=0.04). Bevacizumab significantly increased the risk of grade ≥3 proteinuria, hypertension,haemorrhagic events, neutropenia, and febrile neutropenia [corrected].Conclusions Bevacizumab significantly prolonged OS and PFS when added to first-line platinum-based chemotherapy in patients with advanced NSCLC; no unexpected toxicity was evident.

Integrity signals

Registry

Crossref · 10.1093/annonc/mds590

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Two meta-analyses showed a consistent significant improvement of response rate, progression-free survival, and overall survival for the combination of bevacizumab and platinum-based chemotherapy compared with platinum-based chemotherapy alone in eligible patients with non-squamous NSCLC.

    “two meta-analyses showed a consistent significant improvement of RR, PFS and OS for the combination of bevacizumab and platinum-based chemotherapy, compared with platinum-based chemotherapy alone in eligible patients with NSCC [61,62].”

    From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [62]

Cites

Flagged first, then by citations

1 of the 57 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Soria, J.-C., Mauguen, A., Reck, M., Sandler, A. B., Saijo, N., Johnson, D. H., Burcoveanu, D., Fukuoka, M., Besse, B., & Pignon, J.-P.
Affiliations
  • Inserm (FR)
  • Institut Gustave Roussy (FR)
  • LungenClinic Grosshansdorf (DE)
  • Oregon Health & Science University (US)
  • Kindai University Hospital (JP)
  • The University of Texas Southwestern Medical Center (US)
Corresponding author
Pignon, J.-P.
ORCID
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2013-01
Volume
24
Issue
1
Pages
20-30
ISSN
0923-7534 (ISSN-L)
DOI
10.1093/annonc/mds590
OpenAlex
W2134693386
Cited by
314
References
57
Citations by year
2026: 3 · 2025: 3 · 2024: 9 · 2023: 8 · 2022: 18 · 2021: 26 · 2020: 12 · 2019: 31 · 2018: 23 · 2017: 34 · 2016: 32 · 2015: 46 · 2014: 40 · 2013: 24 · 2012: 3
FWCI
6.11
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Hoffmann-La Roche Ltd
  • Ligue National Contre le Cancer
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
bevacizumab, non-small cell lung cancer, platinum-based chemotherapy, first-line therapy, overall survival, progression-free survival, proteinuria, febrile neutropenia, lung adenocarcinoma, weight loss, prognostic factors
MeSH terms
Bevacizumab, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Organoplatinum Compounds, Survival Analysis, Randomized Controlled Trials as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review